文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性无效治疗时暂停抗VEGF治疗的专家指导

SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY.
PubMed 文献 · Retina · 2020-01-01

本文为Bayer资助的Vision Academy指导文件,通过文献回顾和视网膜专家经验,针对新生血管性年龄相关性黄斑变性对抗VEGF治疗反应不佳的患者,提出判断何时应暂停抗VEGF治疗的算法。算法要求先排除治疗不足或误诊等因素,再换用其他抗VEGF药物,若仍无反应且经过预定时间的「治疗暂停」后仍无改善,可认为治疗无效并暂停抗VEGF。

要点

  • 反应不佳时需先排查治疗不足、误诊或注射/药物并发症等可调整因素。
  • 换用其他抗VEGF药物后反应仍持续不佳,可考虑预定时间的治疗暂停。
  • 治疗暂停后仍无反应变化,可判定抗VEGF治疗无效并暂停。

核心结论

  • 对新生血管性年龄相关性黄斑变性抗VEGF反应不佳者,应先排查可调整因素并换药,经预定时间治疗暂停后仍无反应方可判定无效并暂停治疗。

研究设计与样本

  • 由Bayer资助的Vision Academy指导委员会通过文献回顾结合视网膜专家知识与临床经验制定管理算法。

主要发现

  • 需考虑治疗不足或误诊等可能导致反应不佳的因素,以及注射或药物相关并发症等可能妨碍继续治疗的因素。
  • 换用其他抗VEGF药物后反应仍持续不佳,且预定时间「治疗暂停」后反应无变化,可认为抗VEGF治疗无效。

关键数值与推荐

  • 换用替代抗VEGF药物后反应仍持续不佳,且预定时间治疗暂停后反应无变化,可判定治疗无效并暂停抗VEGF。

临床怎么用

  • 对反应不佳者先评估治疗不足、误诊及注射或药物并发症,再考虑换药。
  • 换药后仍无反应可实施预定时间的治疗暂停,暂停后仍无改善则暂停抗VEGF治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide guidance on the management of patients with neovascular age-related macular degeneration and its subtypes who respond poorly to anti-vascular endothelial growth factor (anti-VEGF) therapy, and to identify cases where suspending anti-VEGF treatment may be warranted. METHODS: Through a literature review and the combined knowledge and clinical experience of retinal experts, the Steering Committee of the Bayer-sponsored Vision Academy developed an algorithm for determining when to suspend anti-VEGF treatment of neovascular age-related macular degeneration in cases of futility. RESULTS: Consideration of factors that may cause suboptimal response to anti-VEGF therapy, such as undertreatment or misdiagnosis of the underlying condition, and factors that may preclude continued treatment, such as injection- or drug-induced complications, is necessary for adjusting treatment protocols in patients who respond poorly to anti-VEGF. If poor response to treatment persists after switching to an alternative anti-VEGF agent and no change in response is observed after withholding treatment for a predetermined period of time ("treatment pause"), anti-VEGF treatment may be considered futile and should be suspended. CONCLUSION: This publication introduces an algorithm to guide the management of neovascular age-related macular degeneration in patients showing poor response to anti-VEGF treatment and provides expert guidance for suspending anti-VEGF treatment in cases of futility.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Wong DT, Lambrou GN, Loewenstein A, et al. SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. Retina. 2020. PMID: 31876889. doi:10.1097/IAE.0000000000002713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。